Estradiol and Levonorgestrel and Ravicti
Determining the interaction of Estradiol and Levonorgestrel and Ravicti and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Glycerol phenylbutyrate may reduce the blood levels and effects of estradiol. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with glycerol phenylbutyrate may decrease the systemic exposure to and therapeutic efficacy of drugs that are substrates of CYP450 3A4. Glycerol phenylbutyrate, its active moiety phenylbutyrate, and active metabolite phenylacetic acid are considered weak CYP450 3A4 inducers in vivo. In healthy subjects, coadministration of glycerol phenylbutyrate (4.4 g orally three times daily for 3 days) with oral midazolam, a sensitive CYP450 3A4 substrate, decreased the peak plasma concentration (Cmax) and systemic exposure (AUC) of midazolam of approximately 25% and 32%, respectively, and increased the mean Cmax and AUC of its metabolite 1-hydroxy midazolam, by 28% and 58%, respectively, compared to administration of midazolam alone. The clinical significance has not been established.
MANAGEMENT: Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.g., oral midazolam) or CYP450 3A4 substrates with a narrow therapeutic index (e.g., alfentanil, oral contraceptives, quinidine, and ciclosporin) should be done with caution and monitoring for reduced efficacy. Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever glycerol phenylbutyrate is added to or withdrawn from therapy.
- "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc, South San Francisco, CA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: estradiol / levonorgestrel
Brand name: Climara Pro
Synonyms: Estradiol and levonorgestrel (transdermal)
Generic Name: glycerol phenylbutyrate
Brand name: Ravicti
Synonyms: Ravicti Oral Liquid
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Estradiol and Levonorgestrel-Ravicti Oral Liquid
- Estradiol and Levonorgestrel-Rayaldee
- Estradiol and Levonorgestrel-Rayos
- Estradiol and Levonorgestrel-Razadyne
- Estradiol and Levonorgestrel-Razadyne (Galantamine Solution)
- Estradiol and Levonorgestrel-Razadyne (Galantamine Tablets)
- Ravicti-Estradiol and levonorgestrel transdermal
- Ravicti-Estradiol and medroxyprogesterone Intramuscular
- Ravicti-Estradiol and norethindrone
- Ravicti-Estradiol and Norethindrone Patch
- Ravicti-Estradiol and Norethindrone Tablets
- Ravicti-Estradiol and norethindrone transdermal